Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma. - Wikidata - wikimedia - TriplyDB

Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma.

Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma.

http://www.wikidata.org/entity/Q37693640

about

Advances in nanomedicine drug delivery applications for HIV therapy.Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques.Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook.

P2860

Q47112878-B1BDAF2E-D4C8-4E7C-9DE8-093913890FC1 Q47142890-D2A5B174-5E06-4033-95AA-B543B9FB6C64 Q47760026-650B311B-0BAE-438F-A000-3B85C8C74AF3

P2860

Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma.

http://www.wikidata.org/entity/Q37693640

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 17 January 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Long-acting combination anti-H ...... han in blood cells and plasma.

@en

Long-acting combination anti-H ...... han in blood cells and plasma.

@nl

type

label

Long-acting combination anti-H ...... han in blood cells and plasma.

@en

Long-acting combination anti-H ...... han in blood cells and plasma.

@nl

prefLabel

Long-acting combination anti-H ...... han in blood cells and plasma.

@en

Long-acting combination anti-H ...... han in blood cells and plasma.

@nl

P1433

Q37693640-19737946-7967-4AAE-B74C-2202DCD5A704

P1476

Q37693640-29C15069-C319-4803-A3C6-48FE20ABC81D

P2093

Q37693640-13B8FC75-89BC-4526-B5C2-B60D2FFA12A9

Q37693640-5C7840B5-FBF1-426A-BB5C-CEC37C68E411

Q37693640-7A4F56E9-0C1F-461A-8063-4BBDA364726A

Q37693640-847378F4-8977-453B-8CF1-974997037DFA

Q37693640-90F24C9B-70B0-4C13-8B84-31B90CEB9C7A

Q37693640-9DE447B9-4199-4EB0-97B1-5B601918E978

Q37693640-B5441521-9D05-4718-A5CA-50128AF057B2

Q37693640-F7B01D7D-F9E7-41FD-BFE5-F6D765E38501

P2860

Q37693640-0AECB484-4454-4BA1-9E7B-44073D4C8BF9

Q37693640-254EF1E6-C905-4BB0-9447-6A541A3F4211

Q37693640-42DAFAE6-C8A3-4A05-8D5C-3B3E3C36D4E8

Q37693640-63B8C1DC-5EFD-4E8C-B571-A38E1FA513B1

Q37693640-8C129AAA-842E-4635-9F69-41FDA5039F69

Q37693640-931E0D95-9B4E-43C8-B3CA-212CFB3AA8A5

Q37693640-AE244A72-99CB-4735-92FF-D81D1DC1F354

Q37693640-B2A05374-1E28-468B-BDC8-87B7D37FCE66

Q37693640-C23BCF0B-3C7D-4DA1-AF9C-828591EF1A4B

Q37693640-C4EF8BB7-B6B9-450E-A08E-A6EE24638CFC

P304

Q37693640-51B0D37E-0AA6-4DF4-9B21-7FC252BA267E

P31

Q37693640-BF06C301-8624-48E1-8374-F4911A51AE9F

P356

Q37693640-1B6896BD-D8B6-4C5D-8BDB-054B837EAC68

P407

Q37693640-A1D65B6B-CED2-4950-82F9-297B26500BB9

P433

Q37693640-D37137EA-D5CD-4A6A-8E06-80F590E12BB7

P478

Q37693640-6E1F874B-BB24-490E-BDF7-C70A7F3679C6

P577

Q37693640-AA53BC7B-4FB0-4624-A7AB-DC7A2748FEC0

P698

Q37693640-DD6C2B13-B8DE-44DE-9A5F-7560970D3D07

P921

Q37693640-821AD15F-266F-4780-B57D-777222BAF659

P932

Q37693640-E80EFCDB-F371-4FAF-9FD0-F4C3163BB57D

P356

QAD.0000000000001405

P1433

P1476

Long-acting combination anti-H ...... han in blood cells and plasma.

@en

P2093

Ann C Collier

http://www.w3.org/2001/XMLSchema#string

Carol Collins

http://www.w3.org/2001/XMLSchema#string

Danny D Shen

http://www.w3.org/2001/XMLSchema#string

John C Kraft

http://www.w3.org/2001/XMLSchema#string

Josefin Koehn

http://www.w3.org/2001/XMLSchema#string

Lisa A McConnachie

http://www.w3.org/2001/XMLSchema#string

Loren Kinman

http://www.w3.org/2001/XMLSchema#string

Rodney J Y Ho

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates.

Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations.

Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis.

Persistent HIV-1 replication maintains the tissue reservoir during therapy

Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys.

Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues.

Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy.

Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment.

Chemoprophylaxis With Oral Emtricitabine and Tenofovir Alafenamide Combination Protects Macaques From Rectal Simian/Human Immunodeficiency Virus Infection.

Vital Signs: HIV diagnosis, care, and treatment among persons living with HIV--United States, 2011.

P304

765-770

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAD.0000000000001405

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28099191

http://www.w3.org/2001/XMLSchema#string

P921

P932

5345888

http://www.w3.org/2001/XMLSchema#string